FMO3 and neoplasm: Among the top 18 probesets identified based on DEFB1 expression, we found that 16 of them, including CDH1, COMT, DCN, LUM, HSD17B2, UGP2, CYFIP2, AFM, TPD52L1, HPX, STARD5, EPHA3, SRPX, HGS, PDGFRA, RRAGD and FMO3, were consistently differentially expressed in liver cancer and non-tumor specimens.